 He is the co-author of a 2005 paper that discovered a precursor to the drug.Jean-Pierre Sommadossi, a principal founder of Idenix and a co-founder of Pharmasset, is a former business partner who no longer speaks to Schinazi.In litigation between Idenix and Gilead/Pharmasset, there was an Order denying Idenix’s motion for enhanced damages where the court noted that Schinazi "violated his confidentialy obligations to Idenix, and shared with Pharmasset scientists Idenix's proprietary discoveries relating to treatment of HCV".